% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schweitzer:874452,
author = {Schweitzer, F. and Laurent, S. and Fink, G. R. and Barnett,
Michael H. and Hartung, H. P. and Warnke, C.},
title = {{E}ffects of disease-modifying therapy on peripheral
leukocytes in patients with multiple sclerosis},
journal = {Journal of neurology},
volume = {268},
number = {7},
issn = {0340-5354},
address = {Berlin},
publisher = {Springer85301},
reportid = {FZJ-2020-01453},
pages = {2379-2389},
year = {2021},
abstract = {Modern disease-modifying therapies (DMTs) in multiple
sclerosis (MS) have variable modes of action and selectively
suppress or modulate the immune system. In this review, we
summarize the predicted and intended as well as unwanted
adverse effects on leukocytes in peripheral blood as a
result of treatment with DMTs for MS. We link changes in
laboratory tests to the possible therapeutic risks that
include secondary autoimmunity, infections, and impaired
response to vaccinations. Profound knowledge of the intended
effects on leukocyte counts, in particular lymphocytes,
explained by the mode of action, and adverse effects which
may require additional laboratory and clinical vigilance or
even drug discontinuation, is needed when prescribing DMTs
to treat patients with MS.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5251 - Multilevel Brain Organization and Variability
(POF4-525)},
pid = {G:(DE-HGF)POF4-5251},
typ = {PUB:(DE-HGF)16},
pubmed = {32036423},
UT = {WOS:000515966700001},
doi = {10.1007/s00415-019-09690-6},
url = {https://juser.fz-juelich.de/record/874452},
}